Dipalmitoylation of Radicicol Results in Improved Efficacy Against Tumor Growth and Angiogenesis in Vivo

Overview

Journal Cancer Sci

Specialty Oncology

Date 2007 Jan 20

PMID 17233839

Citations 3

Authors

Tsutomu Oikawa

Chizuko Onozawa

Sachi Kuranuki

Yasuhiro Igarashi

Mayumi Sato

Hiromi Ashino

Mariko Shimamura

Masakazu Toi

Shinichi Kurakata

Affiliations

Soon will be listed here.

Abstract

Tumor-related angiogenesis is likely to be a potential target for the treatment of cancer. One key to develop this angiostatic strategy would be to find useful angiogenesis inhibitors. Here we report the effects of radicicol, a microbial angiogenesis inhibitor that we previously identified using the chorioallantoic membrane assay, and its novel analog, 14,16-dipalmitoyl-radicicol, on tumor angiogenesis and growth. As expected for agents containing a penolic hydroxyl group, systemic administration of radicicol had little or no effect on neovascularization triggered by a M5076 mouse tumor cell line or a RMT-1 rat mammary carcinoma cell line established from autochthonous rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene in a mouse dorsal air sac assay system. The agent did not show growth-inhibitory activity against either transplantable M5076 tumors or autochthonous 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. In contrast, 14,16-dipalmitoyl-radicicol potently suppressed tumor angiogenesis and growth in these experimental models. Furthermore, the analog significantly prolonged the survival rate of M5076-implanted mice. Although not stronger than radicicol, it dose-dependently inhibited embryonic angiogenesis in the chorioallantoic membrane assay, the dose required for half-maximal inhibition (ID(50)) value being 23 microg (27 nmol) per egg, and showed concentration-dependent antiproliferative activity against microvascular endothelial cells in vitro. These data suggest that 14,16-dipalmitoyl-radicicol is a promising antitumor agent with antiangiogenic activity.

Citing Articles

Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90.

Henke A, Franco O, Stewart G, Riddick A, Katz E, Hayward S Cancers (Basel). 2016; 8(9).

PMID: 27563925 PMC: 5040979. DOI: 10.3390/cancers8090077.

Interaction of cepharanthine with immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α inhibitors.

Haginaka J, Kitabatake T, Hirose I, Matsunaga H, Moaddel R Anal Biochem. 2012; 434(1):202-6.

PMID: 23219559 PMC: 4632246. DOI: 10.1016/j.ab.2012.11.010.

Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo.

Kunimasa K, Ikekita M, Sato M, Ohta T, Yamori Y, Ikeda M Cancer Sci. 2010; 101(11):2462-9.

PMID: 20670297 PMC: 11158917. DOI: 10.1111/j.1349-7006.2010.01668.x.

References

Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O, Iwaguchi T . Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol. 1990; 178(2):247-50. DOI: 10.1016/0014-2999(90)90483-m. View

Shibuya M . Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci. 2003; 94(9):751-6. PMC: 11160205. DOI: 10.1111/j.1349-7006.2003.tb01514.x. View

Toi M, Bando H, Ramachandran C, Melnick S, Imai A, Fife R . Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis. 2004; 6(2):121-8. DOI: 10.1023/B:AGEN.0000011802.81320.e4. View

Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S . Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983; 221(4612):719-25. DOI: 10.1126/science.6192498. View

Kwon H, Yoshida M, Fukui Y, Horinouchi S, Beppu T . Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 1992; 52(24):6926-30. View

Oikawa T, Murakami K, Sano M, Shibata J, Wierzba K, Yamada Y . A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells. Jpn J Cancer Res. 2001; 92(11):1225-34. PMC: 5926657. DOI: 10.1111/j.1349-7006.2001.tb02144.x. View

Aoki S, Cho S, Ono M, Kuwano T, Nakao S, Kuwano M . Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs. 2006; 17(3):269-78. DOI: 10.1097/00001813-200603000-00005. View

Ueda Y, Yamagishi T, Samata K, Ikeya H, Hirayama N, Takashima H . A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155. Mol Cancer Ther. 2003; 2(11):1105-11. View

Ferrara N, Kerbel R . Angiogenesis as a therapeutic target. Nature. 2005; 438(7070):967-74. DOI: 10.1038/nature04483. View

10.

Oikawa T, Onozawa C, Inose M, Sasaki M . Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo. Biol Pharm Bull. 1995; 18(9):1305-7. DOI: 10.1248/bpb.18.1305. View

11.

Matsumoto K, Nakamura T . NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 2003; 94(4):321-7. PMC: 11160298. DOI: 10.1111/j.1349-7006.2003.tb01440.x. View

12.

Kim M, Kwon H, Lee Y, Baek J, Jang J, Lee S . Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4):437-43. DOI: 10.1038/86507. View

13.

Oikawa T, Ito H, Ashino H, Toi M, Tominaga T, Morita I . Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis. Eur J Pharmacol. 1993; 241(2-3):221-7. DOI: 10.1016/0014-2999(93)90206-w. View

14.

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

15.

TAKATORI T, Koizumi T, Tokui T, Mitsuhashi Y, Shiraishi A, Tsuruo T . Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells. Cancer Chemother Pharmacol. 1995; 35(4):283-90. DOI: 10.1007/BF00689446. View

16.

Conway E, Collen D, Carmeliet P . Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001; 49(3):507-21. DOI: 10.1016/s0008-6363(00)00281-9. View

17.

Manach C, Scalbert A, Morand C, Remesy C, Jimenez L . Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004; 79(5):727-47. DOI: 10.1093/ajcn/79.5.727. View

18.

Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T . Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res. 1993; 53(18):4262-7. View

19.

Yano S, Nishioka Y, Goto H, Sone S . Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci. 2003; 94(6):479-85. PMC: 11160313. DOI: 10.1111/j.1349-7006.2003.tb01469.x. View

20.

Soga S, Neckers L, Schulte T, Shiotsu Y, Akasaka K, Narumi H . KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 1999; 59(12):2931-8. View